Milestone Pharmaceuticals Inc. remains a Strong Buy, despite recent volatility and a 37% stock decline since FDA approval of Cardamyst. Cardamyst's rapid-acting efficacy, expanding insurance coverage, and unique market position underpin a compelling medium-term ramp in prescriptions and revenue. International expansion and a Phase 3 trial for AFib-RVR could significantly enlarge MIST's addressable market and long-term growth prospects.